Technical Analysis for IBRX - ImmunityBio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | -4.81% | |
| Wide Bands | Range Expansion | -4.81% | |
| Shooting Star Candlestick | Bearish | -8.21% | |
| Wide Bands | Range Expansion | -8.21% | |
| Wide Bands | Range Expansion | -10.66% | |
| Up 3 Days in a Row | Strength | -10.66% | |
| Earnings Movers | Other | -5.05% | |
| Wide Bands | Range Expansion | -5.05% | |
| Narrow Range Bar | Range Contraction | -4.34% | |
| Earnings Movers | Other | -4.34% |
| Alert | Time |
|---|---|
| Down 5% | about 1 hour ago |
| Possible NR7 | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 5 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Average Volume | 7,910,836 |
| 200-Day Moving Average | 3.83 |
| 50-Day Moving Average | 6.21 |
| 20-Day Moving Average | 7.34 |
| 10-Day Moving Average | 8.34 |
| Average True Range | 0.94 |
| RSI (14) | 57.08 |
| ADX | 34.21 |
| +DI | 31.92 |
| -DI | 15.01 |
| Chandelier Exit (Long, 3 ATRs) | 7.70 |
| Chandelier Exit (Short, 3 ATRs) | 7.60 |
| Upper Bollinger Bands | 10.41 |
| Lower Bollinger Band | 4.27 |
| Percent B (%b) | 0.62 |
| BandWidth | 83.62 |
| MACD Line | 0.72 |
| MACD Signal Line | 0.72 |
| MACD Histogram | -0.0065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.26 | ||||
| Resistance 3 (R3) | 9.32 | 9.01 | 9.06 | ||
| Resistance 2 (R2) | 9.01 | 8.71 | 8.97 | 9.00 | |
| Resistance 1 (R1) | 8.55 | 8.53 | 8.40 | 8.49 | 8.93 |
| Pivot Point | 8.24 | 8.24 | 8.16 | 8.20 | 8.24 |
| Support 1 (S1) | 7.78 | 7.94 | 7.63 | 7.72 | 7.27 |
| Support 2 (S2) | 7.47 | 7.76 | 7.43 | 7.20 | |
| Support 3 (S3) | 7.01 | 7.47 | 7.14 | ||
| Support 4 (S4) | 6.95 |
